Subcutaneous Injection Is the Route of the Approved Analogues, Not of Peptides in General — and the Research Market Applies It to Everything

Every peptide drug a patient administers to themselves is labelled subcutaneous. That is a fact about which peptides got approved, not about the molecule class. Several compounds sold as subcutaneous research vials have a human record that is entirely intravenous, intramuscular or intranasal.

Robert F · Edited by Caroline S · Published 2026-09-19

Illustration: Clear glass vials with lyophilized powder and an empty vial on a slate surface. — Illustration

Almost every research peptide sold today is sold as a lyophilised vial to be reconstituted and injected subcutaneously. The route is so uniform across the market that it reads as a property of the molecules.

It is not. It is a property of which peptides happened to get approved, and for several compounds in this catalogue it does not match the route by which their human evidence was generated.

What the route is

Subcutaneous injection places a dose into the layer of fat between the skin and the muscle. From that depot it is absorbed into the circulation over a period of hours, rather than arriving all at once as an intravenous dose does.

Two consequences follow, and they are the reason the route dominates outpatient medicine:

It does not require a vein, so it does not require a clinician.
It produces a slower, flatter exposure curve than an intravenous dose of the same size.

Everything else — needle length, gauge, dead space, the choice of site — is downstream of those two facts. Those mechanics are covered separately in syringes for peptides and peptide injection sites.

What the approved record shows

We ran a route census against the openFDA drug label API on 19 September 2026, which returns the routes recorded on US labels for a given substance.

Substance	Routes recorded on US labels
Semaglutide	Subcutaneous (4), oral (1)
Tirzepatide	Subcutaneous (8)
Liraglutide	Subcutaneous (22)
Teriparatide	Subcutaneous (8)
Bremelanotide	Subcutaneous (1)
Elamipretide	Subcutaneous (1)
Afamelanotide	Subcutaneous (1)
Setmelanotide	Subcutaneous (1)
Oxytocin	Oral (16), intravenous (10), intramuscular (6)

Eight modern peptide analogues, one route. And then oxytocin, which is a genuine peptide with a genuine label and no subcutaneous route recorded at all.

Chorionic gonadotropin makes the same point from the other direction: the NOVAREL label states the product is for intramuscular use only, and every dose figure in it is intramuscular.

Why the pattern exists, which is not a chemical reason

The eight subcutaneous entries above have something in common that has nothing to do with being peptides: every one of them was developed for a patient to use at home, repeatedly, over a long period.

A chronic outpatient drug needs a route that a person can use unsupervised. Oral delivery is hard for peptides because the digestive tract degrades them — semaglutide's oral products exist precisely because solving that was a development achievement worth pursuing. Intravenous administration needs a vein and a setting. Subcutaneous injection is what is left, and it works.

Oxytocin and chorionic gonadotropin are the two oldest peptide drugs in this catalogue, and both were developed for procedures performed by a clinician. Their routes reflect that. There is no chemistry here, only what each drug was for.

The inference the market draws — peptides are subcutaneous — reverses the causation. The approved peptides are subcutaneous because subcutaneous drugs are what got developed for the uses that were pursued.

Where the research market's route and the evidence diverge

This is the part that changes how a dose figure should be read.

Compound	Sold as	Human evidence was
DSIP	Subcutaneous vial	Intravenous — every administration in the sleep studies behind the circulating figure, usually by infusion under polysomnography
Oxytocin	Nasal spray, subcutaneous vial	Intravenous infusion on the approved label; intranasal in ~290 registered trials, with no approved US intranasal product
Chorionic gonadotropin	Subcutaneous vial	Intramuscular only, per the label
Adipotide	Subcutaneous vial	Subcutaneous — 0.43 mg/kg daily in macaques, 0.03 mg/kg daily starting dose in one terminated human trial

Adipotide is included because it is the case where the routes agree, which is worth seeing alongside the ones where they do not.

The DSIP entry is the cleanest illustration. The dose figure that circulates for it — 25 nmol/kg — comes from studies in which the compound went into a vein, in a clinical setting, under sleep monitoring. It is sold in vials intended for injection under the skin. Nobody has published a study establishing what that same number does by that different route, and the number travels between the two contexts without acknowledgement.

Why a route mismatch is not a technicality

How much of an administered dose reaches the circulation, and how fast, is route-dependent. An intravenous dose is in the blood by definition. A subcutaneous dose is absorbed from a tissue depot over hours, and how completely depends on the molecule, the formulation and the tissue.

A figure generated by one route therefore does not carry to another without a study measuring the relationship. For the modern analogues that study exists, because a development programme is required to produce it. For the research-market compounds it generally does not.

So when a figure derived from intravenous human evidence appears on a subcutaneous vial's listing, an assumption has been made silently: that the two routes deliver comparably. That assumption may be reasonable for some molecules. It has not been tested for these ones, and the page that states the figure almost never says so.

This is the same class of problem as the unit mismatch documented for potency-dosed compounds and the cycle lengths nobody has measured: a number is carried from where it was generated to where it is used, and the step in between goes unstated.

What can be checked

The route census above is reproducible against a public API in a few minutes. The labels are public documents. What a given vendor's listing states about route is on its own page.

What no source supplies, for most of this catalogue, is the study that would justify moving a figure from one route to the other. The peptide dosage chart records, per compound, what the record actually reports and where it came from — including, where relevant, by which route.

Sources

openFDA drug label API, route census by substance name for twelve molecules. Read 19 September 2026.
PITOCIN (oxytocin) injection label, Par Health USA, DailyMed set id 6e5a66fc-e507-497c-b5ce-44a8c95898ad, published 21 May 2026. Dosage and Administration. Read 19 September 2026.
DailyMed SPL query, drug name "oxytocin", 41 records classified by dosage form. Read 19 September 2026.
ClinicalTrials.gov API v2, "intranasal oxytocin" (290 registrations). Read 19 September 2026.
ClinicalTrials.gov, NCT01262664, intervention field. Read 19 September 2026.
NOVAREL (chorionic gonadotropin) label, route statement, as recorded on this site's hCG dosage page (read 16 September 2026).
Schneider-Helmert, Giusti and the DSIP sleep and endocrine studies, route and dose as recorded on this site's DSIP dosage page (read 13 September 2026).

Peptifact facts

An openFDA route census run on 19 September 2026 returns SUBCUTANEOUS as the only injection route recorded for semaglutide, tirzepatide, liraglutide, teriparatide, bremelanotide, elamipretide, afamelanotide and setmelanotide.
The same census returns no subcutaneous route for oxytocin at all: ORAL 16, INTRAVENOUS 10 and INTRAMUSCULAR 6. The PITOCIN label states that for induction or stimulation of labor, intravenous infusion by the drip method is the only acceptable method of parenteral administration.
The NOVAREL chorionic gonadotropin label states the product is for intramuscular use only.
Every human administration in the DSIP sleep studies opened for this site's DSIP page was intravenous, by injection or infusion into a vein, usually under polysomnography. The research market sells DSIP as a lyophilised vial for subcutaneous use.
Roughly 290 registered studies administer intranasal oxytocin, a formulation with no approved product in the US label database.
The subcutaneous route deposits a drug into the fat layer beneath the skin, from which it is absorbed into the circulation over a period of hours. It is slower than intravenous administration, which places the dose directly into the blood, and it is the route that makes self-administration practical because it does not require a vein.
The pattern in the approved record is explained by what got developed rather than by chemistry: the modern peptide analogues were designed for outpatient chronic use, which requires a route a patient can use unsupervised, and subcutaneous is that route.
Two older peptides with long clinical histories — oxytocin and chorionic gonadotropin — are labelled for intravenous or intramuscular administration and are the two in this catalogue that cannot be self-administered subcutaneously under their labels at all.
The one compound in this catalogue whose human and animal records both used the subcutaneous route at a stated dose is adipotide: 0.43 mg/kg daily for 28 days in rhesus macaques, and a 0.03 mg/kg daily starting dose for 28 days in its one terminated human trial.
A route stated on a research vial's listing is a seller's description of intended use. It is not a finding, and for several compounds in this catalogue it does not match the route by which the compound's human evidence was generated.

Frequently asked questions

What does subcutaneous injection mean?

It means the dose is placed into the layer of fat beneath the skin rather than into a vein or a muscle. From there it is absorbed into the circulation over hours rather than immediately. The practical consequence is that it does not require a vein or clinical supervision, which is why it is the route used by every peptide drug designed for a patient to administer at home — insulin, the GLP-1 analogues, teriparatide and the others.

Are peptides always injected subcutaneously?

No, and the impression that they are comes from which peptides got approved rather than from the molecules. An openFDA route census on 19 September 2026 shows subcutaneous as the only recorded injection route for semaglutide, tirzepatide, liraglutide, teriparatide, bremelanotide, elamipretide, afamelanotide and setmelanotide — every one of them a modern analogue developed for outpatient chronic use. The same census shows oxytocin as oral, intravenous and intramuscular with no subcutaneous route recorded, and the chorionic gonadotropin label specifies intramuscular use only.

Do the research vials match the route the evidence used?

For several compounds, no. This site's DSIP page records that every human administration in the sleep studies behind the circulating dose figure was intravenous — usually by infusion, under polysomnography — while the research market sells DSIP as a lyophilised vial for subcutaneous use. Oxytocin is a starker case: the entire non-obstetric literature uses the intranasal route, for which no approved US product exists, while the approved product is an intravenous infusion. A route stated on a vendor listing is a description of intended use, not a finding.

Does the route change the dose?

It can change it substantially, and that is why the mismatch matters rather than being a technicality. How much of an administered dose reaches the circulation, and how quickly, depends on the route; an intravenous dose is fully in the blood by definition, while a subcutaneous dose is absorbed over hours from a tissue depot. A figure generated by one route does not transfer to another without a study that measures the transfer. For most compounds in this catalogue no such study exists, which means a subcutaneous figure derived from intravenous evidence is an assumption rather than a conversion.

Why did all the approved peptide drugs end up subcutaneous?

Because of what they were developed for. A drug intended for chronic outpatient use has to be administrable by the patient, repeatedly, without a clinic visit, and subcutaneous injection is the route that makes that possible. Oral delivery is difficult for peptides because the digestive tract degrades them, and intravenous administration requires a vein and supervision. The approved peptide analogues are overwhelmingly chronic outpatient drugs, so they are overwhelmingly subcutaneous. It is a fact about the development pipeline, not a property of peptides.

Is subcutaneous the same as intramuscular?

No. Intramuscular injection places the dose into muscle tissue, which is more vascular than subcutaneous fat, and the two routes produce different absorption profiles. The distinction is made explicitly in approved labelling: the NOVAREL chorionic gonadotropin label states the product is for intramuscular use only, and the PITOCIN label specifies that intravenous infusion by the drip method is the only acceptable method of parenteral administration for labor induction. Where a label is that specific about route, it is not treating the routes as interchangeable.

How does this relate to injection sites?

They are two separate questions. This page is about which route the human evidence for a compound actually used. Which anatomical sites a subcutaneous injection may be given at, and what the labels say about whether the site affects absorption, is covered on this site's peptide injection sites page — where the finding is that four approved labels specify four different site lists and three of them state in their own pharmacokinetics sections that the site made no meaningful difference to exposure.